257 related articles for article (PubMed ID: 14559810)
1. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer.
Ayala G; Wang D; Wulf G; Frolov A; Li R; Sowadski J; Wheeler TM; Lu KP; Bao L
Cancer Res; 2003 Oct; 63(19):6244-51. PubMed ID: 14559810
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy.
Sasaki T; Ryo A; Uemura H; Ishiguro H; Inayama Y; Yamanaka S; Kubota Y; Nagashima Y; Harada M; Aoki I
Pathol Res Pract; 2006; 202(5):357-64. PubMed ID: 16516405
[TBL] [Abstract][Full Text] [Related]
3. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
4. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
5. Prevalent overexpression of prolyl isomerase Pin1 in human cancers.
Bao L; Kimzey A; Sauter G; Sowadski JM; Lu KP; Wang DG
Am J Pathol; 2004 May; 164(5):1727-37. PubMed ID: 15111319
[TBL] [Abstract][Full Text] [Related]
6. Identification of phosphorylated proteins involved in the oncogenesis of prostate cancer via Pin1-proteomic analysis.
Endoh K; Nishi M; Ishiguro H; Uemura H; Miyagi Y; Aoki I; Hirano H; Kubota Y; Ryo A
Prostate; 2012 May; 72(6):626-37. PubMed ID: 21809350
[TBL] [Abstract][Full Text] [Related]
7. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
8. Pin1 is overexpressed and correlates with poor prognosis in gastric cancer.
Shi M; Chen L; Ji J; Cai Q; Yu Y; Liu B; Zhu Z; Zhang J
Cell Biochem Biophys; 2015 Mar; 71(2):857-64. PubMed ID: 25280783
[TBL] [Abstract][Full Text] [Related]
9. Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression.
Fukuchi M; Fukai Y; Kimura H; Sohda M; Miyazaki T; Nakajima M; Masuda N; Tsukada K; Kato H; Kuwano H
Int J Oncol; 2006 Aug; 29(2):329-34. PubMed ID: 16820873
[TBL] [Abstract][Full Text] [Related]
10. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
11. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
14. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
15. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
[TBL] [Abstract][Full Text] [Related]
16. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
[TBL] [Abstract][Full Text] [Related]
17. The significance of monoamine oxidase-A expression in high grade prostate cancer.
Peehl DM; Coram M; Khine H; Reese S; Nolley R; Zhao H
J Urol; 2008 Nov; 180(5):2206-11. PubMed ID: 18804811
[TBL] [Abstract][Full Text] [Related]
18. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
19. Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction.
Chen SY; Wulf G; Zhou XZ; Rubin MA; Lu KP; Balk SP
Mol Cell Biol; 2006 Feb; 26(3):929-39. PubMed ID: 16428447
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.
Cohen BL; Gomez P; Omori Y; Duncan RC; Civantos F; Soloway MS; Lokeshwar VB; Lokeshwar BL
Int J Cancer; 2006 Sep; 119(5):1082-7. PubMed ID: 16557596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
